(ABBV) stock has risen 1.5% over the past week, but is down 5.5% over the past month and up 7.9% over the last year. Wall Street’s analysts are moderately bullish, with a 12‑month price target of $253.37, implying meaningful upside from the last close at $203.89.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Matt Phipps reiterated his Buy rating on ABBV with a $203 price target after a stronger‑than‑expected first quarter. AbbVie reported adjusted EPS of $2.65, beating both his estimate and consensus, and delivered $15 billion in revenue versus expectations of about $14.7–$14.8 billion.
Phipps highlighted continued strength in AbbVie’s immunology franchise, where drugs like Skyrizi and Rinvoq posted robust double‑digit growth. He also pointed to impressive performance in the neuroscience segment, with strong gains from Vyalev, Qulipta, Ubrelvy, Botox Therapeutic, and Vraylar.
Management’s confidence showed as they raised full‑year 2026 adjusted EPS guidance, edging above both prior guidance and Street estimates. This reflects momentum across key growth areas even as some products like Juvederm face ongoing pressure and aesthetics overall track roughly in line with expectations.
Gary Nachman at Canaccord Genuity also reiterated a Buy on ABBV and lifted his price target from $262 to $265, seeing further upside from current levels. He cited solid first‑quarter momentum across Immunology, Neuro, Oncology, and Aesthetics, backed by a growing pipeline and management’s view that the market still underestimates long‑term potential in key franchises.
Nachman emphasized that Skyrizi and Rinvoq, along with AbbVie’s neuroscience portfolio, remain underappreciated growth drivers that could support the company well into the next decade. He also noted AbbVie’s financial flexibility for future deals and its attractive 3.5% dividend yield, making the stock appealing for investors seeking both growth and income.
This N‑star analyst ranks #4273 out of 12160, with a 41.79% success rate and 2.40% average return per rating. This N‑star analyst ranks #8078 out of 12160, with a 45.62% success rate and 0.00% average return per rating.
Never miss a stock rating. Find all the latest ratings on TipRanks’ Top Wall Street Analysts page.